DOCSLIB.ORG

FY 2006 Expenditures

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FY 2006 Expenditures Detail Expenditures by Sponsor Name FY06 Expenditures Federal National Cancer Institute 46,389,747.32 National Institute of Heart, Lung, and Blood 38,933,073.34 National Institute of General Medicine Science 30,569,475.01 National Institute of Child Health and Human Development 29,209,397.69 National Institute of Allergy and Infectious Diseases 25,977,414.77 National Science Foundation - Research 23,699,414.69 US Department of Education 23,610,554.80 US Agency for International Development 22,270,234.21 National Institute of Mental Health-NIH 19,289,359.96 National Institute of Diabetes, Digestive and Kidney Diseases 18,205,145.20 National Center for Research Resources 15,059,723.86 National Institute of Environmental Health Sciences 11,882,721.84 National Institute of Neurologic Disorders and Stroke 10,465,067.88 Centers for Disease Control 9,780,400.07 US Environmental Protection Agency - GRANTS 8,650,197.74 National Institute of Dental and Craniofacial Research 7,468,619.25 National Institute on Alcohol Abuse and Alcoholism 7,049,705.16 National Institute of Arthritis Musculoskeletal Skin Disease 5,456,642.81 National Center for Chronic Disease Prev and Health Promo(CDC) 5,172,521.01 Bureau of Health Professions 5,136,450.79 National Institute on Drug Abuse 4,318,215.39 National Institute of Nursing Research 4,155,623.05 National Institute on Aging 4,144,051.99 National Institute of Biomedical Imaging and Bioengineering 3,927,276.05 Maternal and Child Health Bureau 3,521,444.02 US Army Medical Research 3,508,171.00 US Department of Energy 2,905,554.43 National Institute for Occupational Safety and Health 2,343,257.60 National Institute on DeafnessandOther Communication Disorders 2,213,174.50 Fogarty International Center 2,123,427.24 National Eye Institute 2,012,682.17 National Aeronautics and Space Administration 1,972,023.71 US Air Force Office of Scientific Research 1,832,866.77 National Center for Complementary and Alternative Medicine 1,821,123.44 Agency for Healthcare Research and Quality 1,797,384.70 Small Business Administration 1,727,733.63 US Federal Highway Administration 1,709,282.87 National Center for Human Genome Research 1,595,849.92 US Department of Defense 1,569,823.67 Child Care Bureau 1,547,804.03 Office of Naval Research 1,535,784.96 National Center for Injury Prevention and Control 1,521,266.09 Natl Ctr Minority Hlth and Hlth Disparities 1,052,654.04 National Library of Medicine 1,035,804.67 US Army Research Office 1,026,777.44 Administration for Children, Youth and Families 1,022,187.07 Institute of Museum and Library Services 917,141.21 Administration on Developmental Disabilities 845,140.27 Naval Air Warfare Center 687,228.01 HIV/AIDS Bureau /prev: Bureau of Hlth Resources Development 685,218.20 US Department of Agriculture 604,057.43 Office of Rural Health Policy 547,613.73 National Institute of Dental Research 497,366.83 1 of 24 OSR FY06 Annual Report Appendix 4 Detail Expenditures by Sponsor Name FY06 Expenditures Federal (continued) Health Resources and Services Administration 493,478.34 Head Start Bureau 486,587.39 National GeoSpatial-Intelligence Agency 441,814.57 Dod-Defense Supp Srv 440,756.99 US Department of Commerce 427,135.52 National Highway Traffic Safety Administration 357,468.14 National Highway Traffic Safety Administration 330,578.83 National Center for Human Genome Research 301,548.27 US Department of Justice 291,735.37 National Center on Child Abuse 251,468.58 Indian Health Services 247,338.95 Division of Medicine 240,522.27 Women's Health Initiative (NIH) 230,364.03 National Endowment for the Humanities 144,943.62 US Department of Homeland Security 141,834.57 National Historical Publications and Records Commission 109,532.65 National Center for Research Resources 94,184.24 United States Department of State 72,856.97 National Endowment for the Arts 58,373.07 Food and Drug Administration 55,236.93 United States Naval Research Laboratory 50,911.91 National Institute on Aging 39,286.43 Centers for Medicare and Medicaid Services 37,904.32 US Army Corps of Engineers 31,611.80 Bureau of Primary Health Care 28,536.94 US Department of Housing and Urban Development 26,950.82 Substance Abuse and Mental Health Services Admininstration 25,151.76 Uniformed Services University 23,394.59 US Defense Logistics Agency 23,168.56 National Security Agency 21,480.69 US Department of Veterans Affairs 15,000.00 US Peace Corps 13,361.15 Argonne National Laboratory 9,957.37 National Park Service 8,620.03 NIH Clinical Center 7,585.52 Naval Medical Research Center 5,958.68 Medicare Payment Advisory Commission 5,515.43 Ho-Chunk Nation 4,504.90 National Institute of Arthritis Musculoskeletal Skin Disease 3,821.02 United States Fish and Wildlife Services 3,228.49 National Historical Publications and Records Commission 3,099.06 Agency for Health Care Policy and Research (DNU - USE 002467) 1,258.09 US Air Force Office of Scientific Research 775.44 Corporation for National and Community Service 579.33 National Institutes of Health 319.68 Office Of Secretary -198.28 US Army War College USAWC -1,837.40 Federal Subtotal 432,608,583.16 2 of 24 OSR FY06 Annual Report Appendix 4 Detail Expenditures by Sponsor Name FY06 Expenditures Other Bill and Melinda Gates Foundation 9,442,586.92 Robert Wood Johnson Foundation 4,448,948.91 Ford Foundation 3,051,711.40 Cystic Fibrosis Foundation 2,658,185.90 American Cancer Society 1,711,114.75 American Heart Association 1,603,555.95 The Kauffman Foundation 1,083,710.60 Lilly Endowment 977,521.74 Andrew W. Mellon Foundation 944,525.88 NC Biotechnology Center 882,454.84 W. K. Kellogg Foundation 851,005.98 Howard Hughes Medical Institute 791,095.55 Cystic Fibrosis Foundation Therapeutics, Inc. 757,870.32 Medicines for Malaria Venture 678,306.40 Whitaker Foundation 649,314.87 Orange-Person-Chatham Mental Health Center 635,802.87 UNC Income Accounts 592,871.91 Donald W. Reynolds Foundation 578,095.06 The Duke Endowment 534,090.02 Burroughs Wellcome Fund 523,362.39 American Chemistry Council 478,646.41 Corporation for Public Broadcasting 475,614.15 Crohn's and Colitis Foundation of America, Inc. 429,457.46 University of Michigan 388,697.03 Susan G. Komen Breast Cancer Foundation 378,680.89 Leukemia and Lymphoma Society of America 371,418.99 Rutgers University 365,599.23 William T. Grant Foundation 352,884.94 GlaxoSmithKline, Inc 344,859.38 Gerber Foundation 333,450.48 National Alliance Res on Schizophrenia and Depression (NARSAD) 318,661.96 Juvenile Diabetes Research Foundation 299,388.55 The Doris Duke Foundation 286,946.65 March of Dimes Foundation 280,177.15 American Association of Oral and Maxillofacial Surgeons 278,148.46 Annie E. Casey Foundation 277,552.97 Commonwealth Fund 268,546.15 Alzheimer's Association 264,475.38 Intnl Vaccine Instit 258,901.56 American Diabetes Association 257,447.41 American Board of Medical Specialties 257,281.89 Z. Smith Reynolds Foundation 252,501.39 Law School Admission Council 246,902.28 Foundation for Informed Medical Decision Making 233,501.14 W. M. Keck Foundation 224,012.05 Children's Hospital and Regional Medical Center 214,924.25 Foundation for Child Development 192,445.39 Oregon Health Sciences University 182,118.99 John Rex Endowment 177,564.44 Elizabeth Glaser Pediatric AIDS Foundation 174,908.12 Research Triangle Institute 171,157.90 University of California at San Francisco 170,704.37 Intnl Aids Vaccine 169,099.92 Kate B. Reynolds Charitable Trust 167,334.00 3 of 24 OSR FY06 Annual Report Appendix 4 Detail Expenditures by Sponsor Name FY06 Expenditures Other (continued) Arthritis Foundation 165,529.53 Muscular Dystrophy Association 163,987.45 Glaxo SmithKline Foundation 161,450.90 Human Frontier Science Program 160,393.45 Tremaine Foundation 157,565.44 Family Health International 155,451.36 Levi Strauss Foundation 150,122.22 National Multiple Sclerosis Society 146,952.13 Whitehall Foundation 145,458.88 Christopher Reeve Paralysis Foundation 139,599.87 Searle Scholars Program 136,794.17 Duke University 136,410.33 The Brain Tumor Society 134,607.86 Eastern Virginia Medical School 133,516.53 The University of Western Ontario 132,911.46 Spencer Foundation 132,100.56 American Chemical Society-Petroleum Research Fund 130,464.37 University of Toronto 126,924.27 UPS Foundation 120,991.03 University of California 118,722.43 Thrasher Research Fund 114,214.90 Freeman Foundation 106,961.37 State of Vermont 105,684.70 University of Tennessee 104,925.87 Pharmaceutical Research and Manufacturers of America Fdn,Inc 104,429.61 Flight Attendant Medical Research Institute, Inc. 103,658.00 NC Lions Foundation, INC 103,457.75 Johns Hopkins University 103,205.75 Foundation of Hope 100,253.97 American Lung Association 99,381.00 European Commission 98,683.39 S Waxman Cancer Rsrc 97,339.24 Lance Armstrong Foundation 96,314.89 Institute for the Study of Aging 95,732.96 National Hemophilia Foundation 95,685.13 International Vaccine Institute 94,929.00 Technical Assistance Collaborative 93,414.03 Cancer and Leukemia Group B-University of Chicago 92,026.43 Robarts Research Institute 90,983.95 Los Angeles Children and Families First Commission 89,618.24 National Alliance for Autism Research 88,941.49 John S. and James L. Knight Foundation 88,800.25 Hemophilia Of Georgi 88,206.82 Houston Advanced Research Center 88,010.41 Roche Organ Transplantation Research Foundation 86,162.19 Manpower Demonstration Research Corporation 84,611.94 The Stanley Medical Research Institute 84,528.00 NC Academy of Physicians Foundation 83,993.88 NC Rural Economic Development Center, Inc.
Load more

Recommended publications
  • Agenda and Bios
    Purpose: • Inform National Forum members and stakeholders of successful strategies and practices to improve blood pressure control. • Motivate participants to carry out effective strategies to improve blood pressure control in their settings. Welcome Warren A. Jones, MD, FAAFP, National Forum Chair Captain, United States Navy Medical Corps (Ret.) Professor Emeritus of Family Medicine, University of Mississippi Medical Center President, American Academy of Family Physicians, 2001-2002 John M. Clymer Executive Director The National Forum for Heart Disease & Stroke Prevention Collateral Damage from COVID-19 Karen Hacker, MD, MPH Director, National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention Hypertension Control – Driver of Vascular Health Walter Koroshetz, MD Director National Institute of Neurological Disorders and Stroke, National Institutes of Health Answering the Surgeon General’s Call to Action to Control Hypertension: Success Stories Million Hearts® Hypertension Champions Laurence Sperling, MD, Executive Director, Million Hearts®, interviews Dave Faldmo, PA-C, MPAS, Quality Director/Medical Director and Erin Hoefling, RN, Quality Specialist Center Siouxland Community Health Center – Sioux City, Iowa and Nebraska 1 Mobilizing Faith-based and Trusted Community Leaders in Buffalo, New York to Improve Blood Pressure Control in Underserved Communities Meg E. Guerin-Calvert, Senior Managing Director, President, Center for Healthcare Economics and Policy, FTI Consulting interviews Rev. George F. Nicholas, Lincoln Memorial United Methodist Church, Buffalo, New York Maria Whyte, Deputy County Executive, at Erie County, New York Answering the Surgeon General’s Call to Action to Control Hypertension: Next Steps Expanding the Use of Self-Measured Blood Pressure Monitoring Janet S. Wright, MD, FACC, Director (Acting), Division for Heart Disease and Stroke Prevention, National Center for Chronic Disease Prevention and Health Promotion, U.S.
    [Show full text]
  • Global Reach
    Fall 2015 University of Miami School of Nursing and Health Studies GLOBAL REACH UNDERSTANDING LGBT HEALTH LEADERS ON CAMPUS JULIO FRENK TAKES THE HELM fall 2015 UNIVERSITY OF MIAMI SIMULATION HOSPITAL contents AT THE SCHOOL OF NURSING & HEALTH STUDIES EDITORIAL CONTRIBUTORS Join us as we build our future. Marina Alvarez, Rosa M. Lamazares- features Romero, Yolanda Mancilla, Maria Padron, and Ginny Pickles Disparities Research Goes Global UNIVERSITY COMMUNICATIONS 12 Minority undergraduates spend a summer gaining experience and Vice President for Communications inspiration toward becoming scientists. Jacqueline R. Menendez, A.B. ’83 Assistant Vice President for Campus Crusaders Communications and Marketing 18 Improving the lives of college students, particularly those at the University Todd Ellenberg of Miami, is a priority for many SONHS faculty and students. Editorial Director Opening Doors to LGBT Health Meredith Camel, M.F.A. ’12 22 SONHS researchers are furthering the school’s mission to improve the health of all people—no matter what they look like or whom they love. Design Director Scott Fricker Art Director Lisa Kuehnle departments Production Manager Angie Villanueva, A.B. ’12 Leadership Cover Illustration 2 Lisa Kuehnle Dean’s Message Heartbeat is published twice a year 3 by the School of Nursing and Health Vital Signs Studies (SONHS) and the University of 4 New UM President Julio Frenk • Student services gets a new assistant Miami Office of Communications and dean • Twist on interprofessional safety course • Understanding Marketing. Heartbeat is distributed to Overtown • STTI Beta Tau chapter grows • Spotlight on superb alumni, faculty, staff, and friends of the preceptor • New post-master’s in mental health nursing • SONHS SONHS.
    [Show full text]
  • Specialists in Small Molecule Drug Development
    Specialists in Small Molecule Drug Development Dr Stephen Parker, Chairman Dr Tim Mitchell, CEO & Co-Founder Dr John Reader, CSO & Co-Founder Final Results for the Year Ending 30 June 2019 October 2019 www.sareum.co.uk Disclaimer The information contained in this document (“Presentation”) is directed at (i) members or creditors of a corporate body within the meaning of Article 43 of the Financial Services and Markets Act 2000 (Financial Promotions) Order 2005, as amended ("Order"), (ii) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Order, or (iii) those persons to whom it can otherwise be distributed without contravention of article 21 of the Financial Services and Markets Act 2000 (“FISMA”) or to whom it can lawfully be distributed. This Presentation has been prepared by Sareum Holdings PLC (“Company”) and provided to you for information purposes only. This Presentation is not an invitation or inducement to engage in an investment activity for the purposes of FISMA. This Presentation has not been approved by an Authorised Person (as defined in s31 FISMA), as would be required for financial promotions under s21 FISMA and, for the avoidance of doubt, is not a financial promotion for the purposes of FISMA. If, contrary to the above, this Presentation is deemed to be a financial promotion for the purposes of FISMA, the Company relies on the exemptions set out in Articles 19, 43, 59 and 69 of the Order, which exempts companies admitted to trading on relevant markets making certain communications. Please note that any indication of past performance should not be relied upon as a guide to future performance.
    [Show full text]
  • Drug Discovery Chemistry
    Save up to $200! Final Agenda Register by February 23 COVER CHI’s 13th Annual CONFERENCE AT-A-GLANCE PLENARY KEYNOTES SHORT COURSES Drug Discovery AGENDA Plenary April 3-4 Conferences »» Protein-Protein Interactions Keynotes »» Inflammation»&»Autoimmune» Inhibitors Chemistry »» Kinase»Inhibitor»Chemistry Optimizing Small Molecules for Tomorrow's Therapeutics »» GPCR-Targeted Drug Design »» Fragment-Based»Drug» Activity-Based April 2-6, 2018 | San Diego, CA | Hilton San Diego Bayfront Discovery Proteomics: April 4-5 Conferences Protein and »» Ubiquitin»Proteasome»System» Ligand Discovery Inhibitors on a Global Scale CONFERENCE PROGRAMS »» Small»Molecules»for»Cancer» Benjamin F. Cravatt, Immunotherapy PhD, Professor and APRIL 3-4 APRIL 4-5 APRIL 6 Co-Chair, Department »» Macrocyclics»&»Constrained» of Molecular Peptides Medicine, The Protein-Protein Ubiquitin Proteasome Biophysical Approaches »» Targeting»Complex» Scripps Research Membrane»Proteins Institute Interactions System Inhibitors for Drug Discovery April 6 Symposia »» Biophysical»Approaches»for» Lead Optimization Inflammation & Small Molecules for Drug»Discovery for Drug Metabolism Autoimmune Inhibitors Cancer Immunotherapy »» Lead»Optimization»for»Drug» & Safety Metabolism»&»Safety » Targeting Ras » Blood-Brain»Penetrant» Kinase Inhibitor Macrocyclics & Blood-Brain Inhibitors and MYC for the Treatment of Chemistry Constrained Peptides Penetrant Inhibitors HOTEL & TRAVEL Cancer Stephen Fesik, SPONSORSHIP PhD, Professor GCPR-Targeted Targeting Complex Plus Short Courses & EXHIBIT
    [Show full text]
  • 2019 Analyst Day
    2019 Analyst Day March 12, 2019 NASDAQ: LGND 2 Safe Harbor Statement The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it’s partners’ judgment as of the date of this presentation. Words such as “plans,” “believes,” “expects,” “projects,” “could,” “anticipates,” and “will,” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, without limitation, financial projections, expectations regarding research and development programs, potential uses of capital, including any potential dividend or share repurchase program, and the timing of the initiation or compilation of preclinical studies and clinical trials by Ligand and its partners. Actual events or results may differ from Ligand’s expectations due to risks and uncertainties inherit in Ligand’s business, including: Ligand has wide discretion on its use of capital and may choose not to engage in any share repurchases, declare any dividends or pursue acquisitions or internal develop programs; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline;, drug development program benefits may not be realized; Ligand will achieve its guidance in 2019 or thereafter; third party research summarized herein may not be correct or complete; Kyprolis®, EVOMELA® and Zulresso™ may not perform as expected, Ligand relies on collaborative partners for milestone and royalty payments,
    [Show full text]
  • Form 8-K Ligand Pharmaceuticals
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ______________ FORM 8-K ______________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2020 LIGAND PHARMACEUTICALS INCORPORATED (Exact Name of Registrant as Specified in Its Charter) Delaware 001-33093 77-0160744 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification No.) 3911 Sorrento Valley Boulevard, Suite 110 San Diego CA 92121 (Address of principal executive offices) (Zip Code) (858) 550-7500 (Registrant’s Telephone Number, Including Area Code) N/A (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share LGND The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    [Show full text]
  • Milner Symposium 2020
    THERAPEUTICS SYMPOSIUM 2020 GLOBAL THERAPEUTIC ALLIANCE OVERVIEW A SERIES OF ONLINE EVENTS STARTING ON JUNE 12TH ALLIANCE GLOBAL THERAPEUTIC ALLIANCE The Milner Therapeutics Institute encompasses both a research institute and a global outreach programme for collaboration. GLOBAL THERAPEUTIC ALLIANCE Research in the Milner Therapeutics Institute is funded by: Our outreach programme is through the Global Therapeutic Alliance, which aims to build a global research community working together across academia and industry, with Cambridge providing a hub of expertise. The Milner Therapeutics Consortium is central to this aim (p4), and the Alliance has been expanded with the Affiliated Company p8( ) and Affiliated Institutions scheme p37( ) to bring complementary expertise and resources to the community, and provide opportunity to extend collaborative links within and beyond Cambridge. The Affiliated Venture Partnersprogramme, operational since October 2017, provides mentoring and potential funding opportunities for the Milner Therapeutics Institute and its Global Therapeutic Alliance, and especially for our in-house company accelerator Start Codon. 3 CONSORTIUM ASTEX PHARMACEUTICALS MILNER THERAPEUTICS CONSORTIUM The Milner Therapeutics Astex is a leader in innovative drug discovery and Consortium is an academic- development, committed to the fight against cancer and industry partnership, active since diseases of the central nervous system. Astex is developing June 2015. This is underpinned a proprietary pipeline of novel therapies and has multiple
    [Show full text]
  • Penn Nursing 091604.Quark
    Vision for the Future We are committed to a future of national and international partnerships and inter- disciplinary collaborations in advancing knowledge that will influence healthcare policies and practice. We envision our graduates in positions of leadership in national and international healthcare and as academic faculty who are at the leading edge of developing, transmitting, and evaluating fundamental and translational knowledge in promoting healthy lifestyles, enhancing quality of life, and facilitating living with chronic illness for vulnerable populations and nursing-care providers. 2003-2008 University of Pennsylvania School of Nursing Strategic Plan School of Nursing Board of Overseers The Honorable Marjorie Rendell, Chair Mr. Henry P. Baer, Esquire Mr. Mark Baiada The Honorable Phyllis W. Beck Mrs. Carolyn Bennett Mr. Cornelius Bond Dr. Lillian S. Brunner Mr. Gilbert F. Casellas, Esquire Mrs. Eleanor Graham Claus Mrs. Ruth M. Colket Mrs. Eleanor L. Davis Ms. Vernice D. Ferguson Ms. Carol Ware Gates Ms. Rosemarie Greco Mrs. Hannah L. Henderson Mr. Johan Hoegstedt Mr. Stephen J. Heyman, Esquire Mrs. Ellen R. Kapito Mr. Dean C. Kehler Mrs. Norma P. Killebrew Mrs. Sallie G. Korman Mrs. Andrea Berry Laporte Mr. Harvey S. Shipley Miller Mrs. Vivian Weyerhaeuser Piasecki Mr. Robert D. Roy Mr. Robert Ruffolo Dr. Marie A. Savard Rear Admiral Jessie Scott David W. Sweet, Esquire Mr. Alan J. Weber Mr. Michael L. Wert UNIVERSITY of PENNSYLVANIA F ALL 2004 VOLUME 7 Table of Contents NUMBER 2 From the Dean… 2 The Hospital Workplace 4 4 Ann
    [Show full text]
  • NJSNA Receives Accreditation As an Approver and a Provider Delgado and Doran Appointed to Board of Nursing
    & The Institute for Nursing Newsletter Advocating--Positioning--and Educating New Jersey RNs… JOIN US! New Jersey State Nurses Association • 1479 Pennington Road • Trenton, New Jersey 08618 • www.njsna.org • (609) 883-5335 Volume 44 • Number 4 Circulation to 139,000 Registered Nurses and Licensed Practical Nurses in New Jersey October 2014 Inside... Delgado and Doran Appointed to Board of Nursing Yolanda M. Delgado, RN, C, MSN James V. Doran, APN (Anesthesia)/CRNA, MS Yolanda M. Delgado, RN, C, MSN, was appointed James V. Doran, APN to the NJ Board of Nursing (Anesthesia)/CRNA, MS, by Governor Chris Christie was appointed to the NJ Board in March; she is serving on of Nursing by Governor Chris the Regulations Committee. Christie in March. Since 2002, S1152 Passes in the Senate Delgado has been on the St. Doran has been on staff at Peter’s University Hospital University Hospital in the Page 4 staff for more than two Anesthesiology Department; he decades; currently, she is became Chief Nurse Anesthetist a nurse manager for an in 2007. adult medicine/renal unit, Prior to becoming a Yolanda Delgado responsible for a staff of 30 registered professional nurse, and a $2.8 million budget. James Doran Doran’s career began in Also, she is the program coordinator for dual-role emergency medical services at medical interpreter services, partnering with NJ University Hospital, and the NJ Trauma and Research Hospital Association/Health Research and Education Center, where he participated in pharmaceutical research. Trust. As an RN, he headed the Morristown Memorial Hospital At St. Peter’s, Delgado serves as chairperson Emergency Medicine Research program, before returning of Trans-cultural Care Committee, Hispanic to University Hospital as an APN/Anesthesia.
    [Show full text]
  • 4586728.98 in 2005
    Detail Awards by Sponsor Dept Name FY05 Award Federal National Cancer Institute 47,048,096.55 National Institute of Heart, Lung, and Blood 38,794,591.33 National Institute of General Medicine Science 30,400,147.18 National Institute of Child Health & Human Development 29,863,697.92 National Institute of Allergy & Infectious Diseases 27,492,973.12 National Science Foundation - Research 20,659,748.00 National Institute of Diabetes, Digestive & Kidney Diseases 19,575,845.00 National Center for Research Resources 19,179,710.00 National Institute of Mental Health-NIH 16,727,938.80 US Department of Education 15,868,100.00 US Agency for International Development 12,743,904.00 National Institute of Environmental Health Sciences 11,961,787.00 National Institute of Neurologic Disorders and Stroke 11,957,697.00 Centers for Disease Control 10,507,132.00 National Institute of Dental and Craniofacial Research 7,032,009.35 National Institute on Alcohol Abuse & Alcoholism 6,874,910.00 Bureau of Health Professions 5,797,479.00 National Institute of Arthritis Musculoskeletal Skin Disease 4,921,205.00 US Environmental Protection Agency - GRANTS 4,586,728.98 National Institute on Aging 4,159,889.94 National Institute on Drug Abuse 4,111,248.00 National Institute of Nursing Research 4,094,244.00 National Institute of Biomedical Imaging and Bioengineering 4,079,842.59 Maternal and Child Health Bureau 4,049,730.00 National Science Foundation - Training 3,877,378.00 National Center for Chronic Disease Prev & Health Promo(CDC) 3,384,180.00 US Department of Defense
    [Show full text]
  • An Insight Into Our Life Sciences and Healthcare Sector
    An insight into our Life Sciences and Healthcare Sector 2020 allenovery.com 2 An insight into our Life Sciences and Healthcare Sector | 2020 © Allen & Overy LLP 2020 3 Contents Introducing Allen & Overy 04 Full service, international support for the life sciences and healthcare sector 05 M&A/corporate finance 06 Licensing and collaborations 09 Patent litigation 11 Regulatory 13 Dispute resolution/arbitration 14 Equity and debt financing 15 Restructuring 16 Key contacts 17 allenovery.com 4 An insight into our Life Sciences and Healthcare Sector | 2020 Introducing Allen & Overy GEOGRAPHIC SPLIT BY TOTAL NUMBER OF LAWYERS† 141 Central & Eastern Europe 1,016 UK 929 Western Europe 440 129 Asia Pacific 185 Middle East North, Central & South America 77 Africa GLOBAL PRESENCE NORTH AMERICA EUROPE AFRICA ASIA PACIFIC New York Amsterdam Istanbul Casablanca Bangkok Seoul Washington, D.C. Antwerp London Johannesburg Beijing Shanghai Barcelona Luxembourg Hanoi Singapore CENTRAL & Belfast Madrid MIDDLE EAST Ho Chi Minh City Sydney SOUTH AMERICA Bratislava Milan Abu Dhabi Hong Kong Tokyo São Paulo Brussels Moscow Dubai Jakarta* Yangon Bucharest* Munich Perth * Associated office Budapest Paris ** Cooperation office Düsseldorf Prague † All figures represent the Frankfurt Rome financial year 2016/17 Hamburg Warsaw Source: Regional active headcount October 2018 KEY STATISTICS 5,400 2,300 550 40+ Number of staff Number of lawyers Number of partners Offices around the world © Allen & Overy LLP 2020 5 Full service, international support for the life sciences and healthcare sector Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.
    [Show full text]
  • Curriculum Vitae – Jac Wijkmans
    Curriculum Vitae – Jac Wijkmans Jac C.H.M. Wijkmans Jupiterweg 17, 5345 LR Oss +31 (0)6 2439 8484 [email protected] 10 January 1965, Roosendaal en Nispen Linkedin: http://nl.linkedin.com/pub/jac-wijkmans/11/a96/bb8 Work experience INNTREST Consultancy BV, Oss (2014–present) Owner/Senior Consultant Clients: ‒ uniQure Biopharma, Amsterdam: Global Development Project Leader a.i. leading the clinical development (Phase I/II) of gene therapy products for the treatment of the rare orphan neurodegenerative disorders Huntington’s disease and Sanfilippo B. Previously, ad interim project lead for hemophilia B gene therapy development. ‒ Center for Open Innovation in Lead Discovery (COILED), Nijmegen: Project leader, business developer and investor. In 2016, COILED was awarded a 4.4 M€ EFRO grant to valorize the breakthrough academic research of Spinoza laureate Prof. Mihai Netea (Radboudumc, Nijmegen). COILED partners are Radboud University Nijmegen, Radboudumc, Pivot Park Screening Centre, BioAxis Research, Inntrest and Pansynth. ‒ Kenniscentrum Plantenstoffen, Leiden: Business development/project management focused on developing new business concepts and revenue models for the Dutch horticulture sector. Initiatives are centered on the production of high-value plant components and their use in non- traditional markets such as pharmaceuticals, cosmetics, agrochemicals, fragrance and flavors. ‒ Radboud Universiteit, Nijmegen: Conducting feasibility study, drafting business plan and raising funds for new drug discovery center. This center presents a system innovation in pharmaceutical research in which a non-profit, open innovation drug discovery platform is provided to unlock and translate breakthrough academic research towards the development of drug candidates suited for clinical studies. ‒ PAO Farmacie, Zeist: Medicinal chemistry section post-graduate course ‘Quality Management’.
    [Show full text]